Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 14/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 2/20 | 0.41 |
| ▸ | CTSE | P14091 | 2/20 | 0.41 |
| ▸ | PGC | P20142 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099323 | 1.00 | REN (0.47) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL4094876 | 0.85 | SSTR4 (0.44) | RENSSTR4EPHX2 | |
| SCHEMBL4093834 | 0.85 | SSTR4 (0.44) | RENSSTR4EPHX2 | |
| SCHEMBL4106036 | 0.85 | SSTR4 (0.44) | RENSSTR4EPHX2 | |
| SCHEMBL4094874 | 0.85 | SSTR4 (0.44) | RENSSTR4EPHX2 | |
| SCHEMBL4067653 | 0.80 | SSTR4 (0.41) | KCNH2SSTR4 | |
| SCHEMBL3579316 | 0.78 | SSTR4 (0.41) | KCNH2SSTR4 | |
| SCHEMBL4110232 | 0.78 | SSTR4 (0.44) | KCNH2SSTR4 | |
| SCHEMBL3576277 | 0.76 | SSTR4 (0.38) | RENKCNH2SSTR4 | |
| SCHEMBL13177317 | 0.75 | REN (0.64) | RENHTR1AADRA1DHTR2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | REN 6/4885HTR1A 2296/4885ADRA1D 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.